It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Two groups of 16 volunteers were enrolled and vaccinated. The study showed safety and immunogenicity at the doses evaluated.
In experiments conducted in 2004 by the VRC together with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), our vaccine candidate confirmed single-dose protection of monkeys against Ebola. Our results are distinct from the earlier trials in that our vaccine is based on PER.C6® cells, making it suitable for large-scale manufacturing.
Johnson & Johnson completed the tender offer for Crucell N.V. (Crucell) on 22nd February 2011 and declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.
Headquartered in Leiden, the Netherlands, Crucell currently employs 1400 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam.